Clinical Trials for Genentech

Explore 253 clinical trials worldwide

Showing 1-50 of 253 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Genentech

Clinical Trials (253)

NCT07049848
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
PHASE2Not yet recruiting
50 participants
Started: Dec 1, 2025 · Completed: Jan 1, 2030
1 condition2 sponsors1 location
NCT07052695
Mosunetuzumab for CLL MRD Clearance
PHASE1/PHASE2Not yet recruiting
40 participants
Started: Nov 30, 2025 · Completed: Jul 1, 2032
4 conditions2 sponsors2 locations
NCT07059091
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
PHASE2Not yet recruiting
334 participants
Started: Nov 30, 2025 · Completed: May 31, 2031
2 conditions5 sponsors23 locations
NCT06532474
Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies
N/ARecruiting
24 participants
Started: Nov 30, 2025 · Completed: Mar 31, 2027
1 condition2 sponsors1 location
NCT06847542
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
PHASE3Not yet recruiting
250 participants
Started: Nov 18, 2025 · Completed: Oct 12, 2028
1 condition2 sponsors0 locations
NCT06904911
Intra-Arterial Tenecteplase to Improve the Microvascular Hemodynamics After Mechanical Thrombectomy
PHASE2Not yet recruiting
20 participants
Started: Nov 15, 2025 · Completed: Sep 30, 2026
1 condition2 sponsors0 locations
NCT06984341
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
PHASE1Not yet recruiting
162 participants
Started: Nov 1, 2025 · Completed: Nov 1, 2033
1 condition1 sponsor0 locations
NCT07214662
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
PHASE1Not yet recruiting
136 participants
Started: Nov 1, 2025 · Completed: Jul 1, 2029
1 condition1 sponsor0 locations
NCT06492954
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
PHASE1Recruiting
12 participants
Started: Oct 31, 2025 · Completed: Jun 30, 2027
2 conditions2 sponsors1 location
NCT07059494
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
PHASE4Recruiting
40 participants
Started: Oct 31, 2025 · Completed: Aug 1, 2028
1 condition2 sponsors1 location
NCT07214766
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
PHASE1Not yet recruiting
312 participants
Started: Oct 17, 2025 · Completed: Apr 16, 2026
1 condition1 sponsor0 locations
NCT07207148
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
N/ANot yet recruiting
100 participants
Started: Oct 15, 2025 · Completed: Aug 31, 2028
1 condition2 sponsors1 location
NCT07008378
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
PHASE1Recruiting
60 participants
Started: Oct 15, 2025 · Completed: Aug 31, 2032
1 condition2 sponsors1 location
NCT07100106
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
PHASE1/PHASE2Recruiting
285 participants
Started: Oct 7, 2025 · Completed: Jul 31, 2030
1 condition2 sponsors5 locations
NCT06957535
Community-led Navigation to Address Disparities in Mammography Among Native American Women
NARecruiting
200 participants
Started: Oct 2, 2025 · Completed: Mar 31, 2028
1 condition2 sponsors1 location
NCT07181811
Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition in Veterans With Multiple Sclerosis
NANot yet recruiting
30 participants
Started: Sep 30, 2025 · Completed: Jun 1, 2028
1 condition2 sponsors1 location
NCT07113691
Iadademstat + SBRT With Atezo in ES-SCLC
PHASE1Not yet recruiting
15 participants
Started: Sep 30, 2025 · Completed: Sep 30, 2029
1 condition3 sponsors1 location
NCT07024706
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
PHASE2Not yet recruiting
80 participants
Started: Sep 30, 2025 · Completed: Nov 30, 2032
2 conditions3 sponsors0 locations
NCT06979336
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
PHASE2Recruiting
224 participants
Started: Sep 29, 2025 · Completed: Oct 31, 2028
1 condition1 sponsor3 locations
NCT06781385
Intra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion Stroke
PHASE2Enrolling by invitation
40 participants
Started: Sep 22, 2025 · Completed: Dec 31, 2026
1 condition2 sponsors1 location
NCT06828991
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
PHASE2Recruiting
40 participants
Started: Sep 4, 2025 · Completed: Apr 30, 2030
1 condition4 sponsors1 location
NCT07144111
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
PHASE1Recruiting
32 participants
Started: Aug 21, 2025 · Completed: Sep 6, 2026
1 condition1 sponsor4 locations
NCT07001384
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
PHASE1Recruiting
30 participants
Started: Aug 8, 2025 · Completed: Aug 8, 2031
2 conditions3 sponsors7 locations
NCT06790784
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
PHASE3Recruiting
426 participants
Started: Aug 4, 2025 · Completed: Aug 31, 2031
1 condition3 sponsors5 locations
NCT07039266
Food Allergy Registry and Awareness Campaign in Puerto Rico
N/ANot yet recruiting
151 participants
Started: Jul 1, 2025 · Completed: Dec 1, 2026
1 condition2 sponsors0 locations
NCT06801054
Safety Of A Second Dose Of Tenecteplase In Selected Acute Ischemic Stroke Patients Not Responding To The First Dose
PHASE1Not yet recruiting
20 participants
Started: Jul 1, 2025 · Completed: Sep 30, 2026
1 condition5 sponsors1 location
NCT06701682
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
PHASE2Recruiting
200 participants
Started: Jun 21, 2025 · Completed: Feb 8, 2028
4 conditions5 sponsors16 locations
NCT06945900
Emergency Medical Services (EMS) Telehealth to Speed STEMI Reperfusion
N/ARecruiting
35 participants
Started: Jun 18, 2025 · Completed: Dec 31, 2028
1 condition3 sponsors1 location
NCT05870800
Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER
PHASE2Recruiting
28 participants
Started: Jun 15, 2025 · Completed: Jan 1, 2028
3 conditions2 sponsors1 location
NCT06703073
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
PHASE2Recruiting
600 participants
Started: Jun 10, 2025 · Completed: Feb 8, 2028
4 conditions5 sponsors16 locations
NCT06701669
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
PHASE2Recruiting
200 participants
Started: Jun 10, 2025 · Completed: Feb 8, 2028
4 conditions5 sponsors16 locations
NCT06903702
A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
PHASE2Recruiting
100 participants
Started: Jun 4, 2025 · Completed: Jun 30, 2027
1 condition2 sponsors7 locations
NCT07011004
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
PHASE1Recruiting
18 participants
Started: May 30, 2025 · Completed: May 31, 2028
2 conditions2 sponsors7 locations
NCT06934200
Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels
PHASE2Recruiting
32 participants
Started: May 19, 2025 · Completed: Oct 15, 2027
1 condition2 sponsors1 location
NCT06357676
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma
PHASE1/PHASE2Not yet recruiting
27 participants
Started: May 9, 2025 · Completed: Nov 1, 2029
1 condition3 sponsors1 location
NCT06754501
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
PHASE2Recruiting
35 participants
Started: Apr 11, 2025 · Completed: Jul 1, 2029
1 condition3 sponsors1 location
NCT06555133
Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
PHASE2Recruiting
18 participants
Started: Apr 7, 2025 · Completed: Sep 1, 2029
1 condition3 sponsors1 location
NCT06693908
A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis
PHASE1/PHASE2Recruiting
24 participants
Started: Mar 31, 2025 · Completed: May 6, 2026
1 condition1 sponsor1 location
NCT06784947
Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer
PHASE2Active, not recruiting
13 participants
Started: Mar 25, 2025 · Completed: May 31, 2028
3 conditions2 sponsors1 location
NCT06701656
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
PHASE2Recruiting
200 participants
Started: Feb 26, 2025 · Completed: Feb 8, 2028
4 conditions5 sponsors16 locations
NCT06495593
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
PHASE4Recruiting
5 participants
Started: Feb 4, 2025 · Completed: Dec 31, 2025
1 condition2 sponsors1 location
NCT06734208
A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function
PHASE1Recruiting
40 participants
Started: Jan 31, 2025 · Completed: Jun 10, 2026
1 condition1 sponsor4 locations
NCT06522386
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
PHASE2Recruiting
40 participants
Started: Jan 30, 2025 · Completed: Feb 28, 2029
1 condition4 sponsors2 locations
NCT06602453
A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)
PHASE2Recruiting
404 participants
Started: Jan 17, 2025 · Completed: Nov 15, 2027
1 condition1 sponsor35 locations
NCT06765317
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
PHASE2Recruiting
42 participants
Started: Jan 16, 2025 · Completed: Jan 31, 2028
2 conditions2 sponsors7 locations
NCT05859217
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
PHASE2Not yet recruiting
40 participants
Started: Dec 31, 2024 · Completed: Jun 30, 2028
4 conditions3 sponsors4 locations
NCT06616623
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
PHASE1Recruiting
24 participants
Started: Dec 31, 2024 · Completed: Dec 31, 2026
3 conditions2 sponsors1 location
NCT06439485
Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
PHASE1/PHASE2Recruiting
25 participants
Started: Nov 19, 2024 · Completed: Feb 22, 2030
2 conditions3 sponsors1 location
NCT06569680
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
PHASE2Recruiting
35 participants
Started: Nov 19, 2024 · Completed: Dec 1, 2030
1 condition2 sponsors1 location
NCT06603246
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-Obstructive Disease
PHASE1/PHASE2Recruiting
128 participants
Started: Nov 18, 2024 · Completed: Feb 27, 2026
2 conditions1 sponsor7 locations